| MQA-103T | | | |
|---|-----|--|--------------|
| Roll No. | | | |
| ODD SEMESTER EXAMINATION 2022-23 COURSE NAME: M. PHARMA | | | |
| SEMESTER: I | | | |
| SUBJECT: QUALITY CONTROL & QUALITY ASSURANCE | | | |
| TIME: 3 HOU | JRS | | MAX MARKS:75 |

NOTE: Attempt all parts.

PART A

(QUESTION NO. 1TO 10 ATTEMPT ALL QUESTIONS)(2x10)

- 1. QMS, TQM, and QIP all corresponds to –
- A. Quality techniques
- B. Quality abbreviations
- C. Quality parameters
- D. None of the above
- 2. To Approve or reject the starting materials, packaging materials, and intermediate, bulk and finished products is responsibility of which department?
- A) QC
- B) QA
- C) Production
- D) All
- 3. Which type DMF deals with Manufacturing Site.....
- 4. cGMP regulations for pharmaceutical manufacturing comes under which organization domain of US FDA
- A. Center for Biologics Evaluation and Research
- B. Center for Food Safety and Applied Nutrition
- C. Office of Regulatory Affairs (ORA)

| D. Center for Drug Evaluation and Research (CDER) |
|---|
| 5. The scope of sanitation and hygiene covers- |
| A) Personnel |
| B) Premises |
| C) Equipments |
| D) All |
| 6. The objective of FDA- India office is- |
| A). To ensure the safety, quality, and effectiveness of medical products and foodproduced in India for export to the United States. |
| B) Approval of medical products for marketing in India |
| C) Import of drug in India for test and examination |
| D) Manufacture of drugs in USA for the purpose of export to India |
| 7. When the copyright act was passed |
| 8. PIC was established in |
| 9. GMP ensures which of the following Parameters. |
| A) Quality |
| B) Safety |
| C) Efficacy |
| D) All |
| 10. CDER & CBER stands for |
| PART B |
| (OHESTION No. 11TO12ATTEMPT ANV 2)(2±10) |

(QUESTION No. 11TO13ATTEMPT ANY 2)(2x10)

- **11.** Elaborate the three-tier documentation procedure in pharmaceutical industry and enlist the requirements for sanitization and hygiene in GMP.
- 12. Outline the QC test of tablet and capsule during production and at the end of the process.
- **13.** Demonstrate about ICH M4 Guidelines and summarise about M4Q (R1) & M4Q (R2) for registration of pharmaceutical for human use.

PART C

(QUESTION NO. 14 TO 23 ATTEMPT ANY 7)

(7x5)

- **14.** Who formed CPSEA? Enlist some guidelines, objective and function of CPSEA.
- **15.** Contrast between universal test/criteria & specific test/criteria of Q6 A guidelines or Distinguish between CBER & CDER.
- **16.** Illustrate all of the BMR content & display the front-page format, which includes supersedes date, revision number and other information.
- 17. Define MFR. Enlist some general guidelines/instructions while preparing MFR.
- **18.** With reference to packaging and labeling activities, specify line clearance and demonstrate reconciliation of printed packaging material.
- **19.** Enlist the ICH Q series guidelines & summarize ICH guidelines Q3B (R2) for impurities in new drug product.
- **20.** Prepare a flowchart that follows the ICH Q6 A guidelines for establishing acceptance criteria for degradation in new drug products.
- **21.** How to minimize mix up and cross contamination in manufacturing operation and controls.
- 22. Elaborate the concept of QA & QC.